Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Apr 1, 2021
Date Accepted: Feb 15, 2022
Date Submitted to PubMed: Feb 17, 2022

The final, peer-reviewed published version of this preprint can be found here:

Communicating Treatment-Related Symptoms Using Passively Collected Data and Satisfaction/Loyalty Ratings: Exploratory Study

Kudel I, Perry T

Communicating Treatment-Related Symptoms Using Passively Collected Data and Satisfaction/Loyalty Ratings: Exploratory Study

JMIR Cancer 2022;8(2):e29292

DOI: 10.2196/29292

PMID: 35175206

PMCID: 9107057

Exploring Noona Using Passively-Collected Data and Satisfaction/Loyalty Ratings

  • Ian Kudel; 
  • Toni Perry

ABSTRACT

Background:

PRO real-time communication of treatment-related symptoms is increasingly associated with better outcomes including longer survival and less healthcare resource use, but the primary method of collecting this information, static questionnaires, has not evolved.

Objective:

Describe use of noona’s three methods of communicating treatment-related symptoms: 1) noona symptom questionnaires (NSQ) that incorporate branching logic, 2) a diary with NSQ tracking and reporting functionality, and 3) secure messaging and satisfaction, satisfaction with the application and explore, through the use of multivariable analyses, whether patients find value using these features.

Methods:

noona users (n=1,081) that has an active account for more than 30 days, used one of the primary features, responded to the satisfaction/loyalty item and were undergoing active cancer treatment (systemic or radiotherapy) in the United States were included in this study. All study information (metadata, patient activities measured in clicks, satisfaction/loyalty score) were collected via software embedded within noona code. noona use was passively collected and the satisfaction/loyalty question (“How likely are you to recommend noona to another patient.”) popped-up on the noona homepage; users were able to opt-out of answering the item, but those that do answer are not asked again for at least three months.

Results:

noona users expressed a high degree of satisfaction/loyalty when asked to rate how likely they would recommend noona to another patient. Multivariable analyses indicate small, but significant effects for some of the analyses. Use of NSQs were significantly related to satisfaction/loyalty, users of NSQs had significantly higher satisfaction/loyalty than those who did not use any and secure communication use was significantly higher for those who rate the app highly compared to those who did not. These relationship will likely be improved with the use of satisfaction/loyalty questions that focus specifically on feature use.

Conclusions:

noona is well like by respondents and exploratory multivariable analyses demonstrate the potential for using passively and minimally invasive data to demonstrate value. Satisfaction/Loyalty Ratings to explicate noona. Clinical Trial: N/A


 Citation

Please cite as:

Kudel I, Perry T

Communicating Treatment-Related Symptoms Using Passively Collected Data and Satisfaction/Loyalty Ratings: Exploratory Study

JMIR Cancer 2022;8(2):e29292

DOI: 10.2196/29292

PMID: 35175206

PMCID: 9107057

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.